Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03301532 · ClinicalTrials.gov registry record · Phase 2
Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D
A Phase 2 study of GLUT1DS1, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03301532: Completed Phase 2 study of GLUT1DS1, sponsored by University of Texas Southwestern Medical Center.
NCT03301532 is a Phase 2 study of GLUT1DS1 that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03301532, a Phase 2 study of GLUT1DS1, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
To explore triheptanoin (C7 oil) compatibility with the ketogenic diet by evaluating EEG, and seizure rate, glycemia and ketosis in proven G1D patients receiving a ketogenic diet.
Primary Outcome
Change in Ketosis as measured by changes in blood beta-hydroxybutyric acid levels.
Conditions Studied
Interventions
- DRUG Triheptanoin
Study Locations (1)
Texas
- UTexasSouthwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-06-05 |
| Est. Completion | 2022-07-31 |
| Phase | Phase 2 |
What the finished NCT03301532 record still lists
NCT03301532 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with GLUT1DS1 appearing as the primary indexed condition, and to 1 intervention - of which Triheptanoin is the first listed.
NCT03301532 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03301532 about?
NCT03301532 is a clinical study titled "Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D". To explore triheptanoin (C7 oil) compatibility with the ketogenic diet by evaluating EEG, and seizure rate, glycemia and ketosis in proven G1D patients receiving a ketogenic diet.
What is the current status of trial NCT03301532?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2018-06-05. Estimated completion is 2022-07-31.
What conditions does trial NCT03301532 study?
This clinical trial studies the following conditions: GLUT1DS1.
What interventions are being tested in trial NCT03301532?
The interventions under investigation include: Triheptanoin (DRUG).
Who is sponsoring clinical trial NCT03301532?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03301532 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GLUT1DS1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03301532's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI